Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerBiomarker

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1500931

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1500931

Cancer Biomarkers

PUBLISHED:
PAGES: 89 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Cancer Biomarkers Market to Reach $68.9 Billion by 2030

The global market for Cancer Biomarkers estimated at US$23.2 Billion in the year 2023, is expected to reach US$68.9 Billion by 2030, growing at a CAGR of 16.8% over the analysis period 2023-2030. Protein Biomarkers, one of the segments analyzed in the report, is expected to record a 17.4% CAGR and reach US$42.9 Billion by the end of the analysis period. Growth in the Genetic Biomarkers segment is estimated at 16.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $5.9 Billion, While China is Forecast to Grow at 21.8% CAGR

The Cancer Biomarkers market in the U.S. is estimated at US$5.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$18.3 Billion by the year 2030 trailing a CAGR of 21.8% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.4% and 14.1% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 12.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$11.8 Billion by the year 2030.

Introducing Our Exciting New Report Features for 2024

Full access to influencer engagement stats

Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.

Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities

Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas

Complimentary report updates for one year

Competitor coverage with global market shares of major players

Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies

Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 33 Featured) -

  • Abbott Laboratories
  • Agilent Technologiesent
  • Becton, Dickinson and Company
  • Biomerieux Sant
  • Bio-Rad Laboratories
  • Danaher Corporation
  • GE Healthcare
  • Hologic
  • Illuminat
  • Merck & Co.
  • Myriad Genetics
  • Qiagen N.V.
  • Quest Diagnostics
  • Roche Diagnostics
  • Sysmex Corporation
  • Thermo Fisher Scientific
Show more
Product Code: MCP21409

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Cancer Biomarkers - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Cancer Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Protein Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Protein Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Protein Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Genetic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Genetic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Genetic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Research & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Research & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Research & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Prognostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Prognostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Omics Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Omics Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: World 16-Year Perspective for Omics Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Imaging Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Imaging Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: World 16-Year Perspective for Imaging Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: World 16-Year Perspective for Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Other Profiling Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Other Profiling Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: World 16-Year Perspective for Other Profiling Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 53: USA Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: USA 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: USA 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Canada 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Canada 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • JAPAN
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Japan 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Japan 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Japan 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • CHINA
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 89: China Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: China 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: China 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: China 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: China 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • EUROPE
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Europe 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Europe 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Europe 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • FRANCE
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 116: France Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: France 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: France 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 122: France Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: France 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: France 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • GERMANY
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Germany 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Germany 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Germany 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Germany 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Italy 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Italy 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Italy 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Italy 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 152: UK Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: UK 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: UK 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 158: UK Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: UK 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: UK 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Spain 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 167: Spain Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Spain Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Spain 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Spain 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Spain 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Russia 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 179: Russia Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Russia Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Russia 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Russia 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Russia 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Europe 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Europe Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Europe 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Europe 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Europe 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Australia 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 218: Australia Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Australia Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Australia 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Australia 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Australia 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • INDIA
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 227: India Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: India 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 230: India Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: India Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: India 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 233: India Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: India Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: India 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 236: India Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: India Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: India 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: South Korea 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 242: South Korea Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: South Korea Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: South Korea 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: South Korea 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: South Korea 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Rest of Asia-Pacific Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Latin America 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Latin America 16-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Latin America 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Latin America 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Latin America 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Argentina 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 281: Argentina Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Argentina Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Argentina 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Argentina 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Argentina 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Brazil 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 293: Brazil Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Brazil Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Brazil 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Brazil 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Brazil 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Mexico 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 305: Mexico Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Mexico Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Mexico 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Mexico 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Mexico 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 316: Rest of Latin America 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 318: Rest of Latin America Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 319: Rest of Latin America 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 322: Rest of Latin America 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 325: Rest of Latin America 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 328: Middle East 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 331: Middle East 16-Year Perspective for Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 334: Middle East 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 337: Middle East 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 340: Middle East 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 343: Iran 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 344: Iran Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 345: Iran Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 346: Iran 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 349: Iran 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 352: Iran 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 355: Israel 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 356: Israel Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 357: Israel Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 358: Israel 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 361: Israel 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 364: Israel 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 367: Saudi Arabia 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 369: Saudi Arabia Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 370: Saudi Arabia 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 373: Saudi Arabia 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 376: Saudi Arabia 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 379: UAE 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 380: UAE Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 381: UAE Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 382: UAE 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 385: UAE 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 388: UAE 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 391: Rest of Middle East 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 393: Rest of Middle East Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 394: Rest of Middle East 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 397: Rest of Middle East 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 400: Rest of Middle East 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030
  • AFRICA
    • Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Cancer Biomarkers by Application - Diagnostics, Research & Development, Prognostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 403: Africa 16-Year Perspective for Cancer Biomarkers by Application - Percentage Breakdown of Value Sales for Diagnostics, Research & Development, Prognostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 404: Africa Recent Past, Current & Future Analysis for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 405: Africa Historic Review for Cancer Biomarkers by Biomarker Type - Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 406: Africa 16-Year Perspective for Cancer Biomarkers by Biomarker Type - Percentage Breakdown of Value Sales for Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers for the Years 2014, 2024 & 2030
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for Cancer Biomarkers by Cancer Type - Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 409: Africa 16-Year Perspective for Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Colorectal Cancer, Prostate Cancer, Other Cancer Types, Breast Cancer and Lung Cancer for the Years 2014, 2024 & 2030
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for Cancer Biomarkers by Profiling Technology - Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 412: Africa 16-Year Perspective for Cancer Biomarkers by Profiling Technology - Percentage Breakdown of Value Sales for Omics Technologies, Imaging Technologies, Immunoassay and Other Profiling Technologies for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!